Hanke Luca, Tang Hongjian, Schröder Christina, Windisch Paul, Kudura Ken, Shelan Mohamed, Buchali André, Bodis Stephan, Förster Robert, Zwahlen Daniel R
Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.
Department of Nuclear Medicine, Sankt Clara Hospital, Kleinriehenstrasse 30, 4058 Basel, Switzerland.
Cancers (Basel). 2023 Jun 30;15(13):3454. doi: 10.3390/cancers15133454.
Prostate bed radiotherapy (RT) is a major affecter of patients' long-term quality of life (QoL). To ensure the best possible outcome of these patients, dose constraints are key for optimal RT planning and delivery. However, establishing refined dose constraints requires access to patient-level data. Therefore, we aimed to provide such data on the relationship between OAR and gastrointestinal (GI) as well as genitourinary (GU) QoL outcomes of a homogenous patient cohort who received dose-intensified post-operative RT to the prostate bed. Furthermore, we aimed to conduct an exploratory analysis of the resulting data.
Patients who were treated with prostate bed RT between 2010 and 2020 were inquired about their QoL based on the Expanded Prostate Cancer Index Composite (EPIC). Those (n = 99) who received volumetric arc therapy (VMAT) of at least 70 Gy to the prostate bed were included. Dose-volume histogram (DVH) parameters were gathered and correlated with the EPIC scores.
The median age at the time of prostate bed RT was 68.9 years, and patients were inquired about their QoL in the median 2.3 years after RT. The median pre-RT prostate-specific antigen (PSA) serum level was 0.35 ng/mL. The median duration between surgery and RT was 1.5 years. The median prescribed dose to the prostate bed was 72 Gy. A total of 61.6% received prostate bed RT only. For the bladder, the highest level of statistical correlation ( < 0.01) was seen for V10-20Gy, Dmean and Dmedian with urinary QoL. For bladder wall, the highest level of statistically significant correlation ( < 0.01) was seen for V5-25Gy, Dmean and Dmedian with urinary QoL. Penile bulb V70Gy was statistically significantly correlated with sexual QoL ( < 0.05). A larger rectal volume was significantly correlated with improved bowel QoL ( < 0.05). Sigmoid and urethral DVH parameters as well as the surgical approach were not statistically significantly correlated with QoL.
Specific dose constraints for bladder volumes receiving low doses seem desirable for the further optimization of prostate bed RT. This may be particularly relevant in the context of the aspiration of establishing focal RT of prostate cancer and its local recurrences. Our comprehensive dataset may aid future researchers in achieving these goals.
前列腺床放疗(RT)是影响患者长期生活质量(QoL)的主要因素。为确保这些患者获得最佳治疗效果,剂量限制是优化放疗计划和实施的关键。然而,制定精确的剂量限制需要获取患者层面的数据。因此,我们旨在提供关于接受前列腺床剂量强化术后放疗的同质患者队列中,正常组织(OAR)与胃肠道(GI)以及泌尿生殖系统(GU)生活质量结果之间关系的数据。此外,我们旨在对所得数据进行探索性分析。
询问2010年至2020年间接受前列腺床放疗的患者基于扩展前列腺癌指数综合量表(EPIC)的生活质量情况。纳入那些(n = 99)接受前列腺床至少70 Gy容积弧形调强放疗(VMAT)的患者。收集剂量体积直方图(DVH)参数并与EPIC评分进行关联。
前列腺床放疗时的中位年龄为68.9岁,患者在放疗后中位2.3年被询问生活质量情况。放疗前前列腺特异性抗原(PSA)血清水平的中位数为0.35 ng/mL。手术与放疗之间的中位间隔时间为1.5年。前列腺床的中位处方剂量为72 Gy。共有61.6%的患者仅接受前列腺床放疗。对于膀胱,V10 - 20Gy、平均剂量(Dmean)和中位剂量(Dmedian)与泌尿生活质量的统计学相关性最高(< 0.01)。对于膀胱壁,V5 - 25Gy、Dmean和Dmedian与泌尿生活质量的统计学显著相关性最高(< 0.01)。阴茎球部V70Gy与性功能生活质量具有统计学显著相关性(< 0.05)。较大的直肠体积与改善的肠道生活质量显著相关(< 0.05)。乙状结肠和尿道的DVH参数以及手术方式与生活质量无统计学显著相关性。
对于接受低剂量照射的膀胱体积,特定的剂量限制似乎有利于进一步优化前列腺床放疗。在建立前列腺癌及其局部复发的局部放疗的背景下,这可能尤为重要。我们的综合数据集可能有助于未来的研究人员实现这些目标。